A federal judge in Louisiana ruled this week that mifepristone — the most widely used medication abortion pill in the United States — can remain available as it currently stands for the time being, even as the FDA has been ordered to undertake a new safety review of the drug. The ruling maintains the status quo on telehealth abortion access nationally while the broader legal and political battle over the drug’s future continues to escalate.
What the Judge Ruled
Judge Karen Olds of the US District Court for the Western District of Louisiana issued a stay in Louisiana’s case seeking to ban the use of mifepristone through telemedicine. The stay means that, for now, the drug can continue to be prescribed via telehealth consultations and sent by mail across the country — including in states where state governments have attempted to restrict access through separate legal mechanisms.
Attached to the stay were conditions: the FDA has been ordered to complete a new safety review of mifepristone and report back to the court on its progress within six months. Louisiana’s case seeking to ban telehealth prescribing will proceed to trial once that review is complete.
Why Is Mifepristone Under Legal Attack?
Mifepristone has been approved by the FDA for medication abortion since 2000 and has been used by millions of American women. In combination with a second drug, misoprostol, it accounts for the majority of abortions performed in the United States. The drug has an extensive safety record confirmed by multiple independent reviews over more than two decades. However, anti-abortion groups have argued the FDA’s original approval and subsequent access expansions were procedurally flawed and that prescribing via telehealth without in-person examination creates unacceptable safety risks for patients.
The Trump administration’s FDA has signalled it intends to take a harder line, potentially reversing some of the access expansions introduced under the Biden administration. Anti-abortion Republicans in Congress have also become more assertive in recent weeks, with Senator Josh Hawley of Missouri introducing a bill that would remove the FDA’s full approval of the drug.
The FDA’s New Safety Study
The FDA confirmed in February 2026 that it is conducting a new safety study of mifepristone. The agency said it plans to complete the review “as soon as possible while ensuring we are not cutting any corners from a scientific research standpoint.” Abortion rights advocates argue the review is politically motivated rather than scientifically driven, pointing to the overwhelming body of existing evidence supporting the drug’s safety.
A peer-reviewed study published in the Journal of the American Medical Association (JAMA) in early April 2026 found that mifepristone was safe enough to be sold over the counter without a prescription — a finding that directly contradicts the direction of the current regulatory process.
What This Means for Patients
For now, patients in states where telehealth abortion is legal can continue to access mifepristone by mail through licensed providers. The ruling provides no certainty about the long-term future of this access, however. For patients in states that have already banned abortion or telehealth prescribing through state law, the federal court ruling does not override those state-level restrictions.
Healthcare advocates are urging patients and providers to stay closely informed about the evolving legal landscape, which is changing at an accelerating pace and varies significantly by state.
Reaction From Both Sides
Abortion rights groups welcomed the stay as a temporary reprieve. “This ruling keeps the door open for now, but we are under no illusions — the attempts to restrict this essential medication will continue,” said Nancy Northup of the Center for Reproductive Rights. Anti-abortion organisations expressed frustration but said they remain confident the FDA review will ultimately support their case for restrictions.
Looking Ahead
The outcome of the FDA safety review — expected within six months — could significantly shape access to medication abortion across the country for years to come. Legal analysts expect the case to continue working through the courts regardless of the review’s findings, with a potential return to the Supreme Court a realistic possibility in the medium term.